)
)
)
How Competition Law Considerations are Reshaping Life Science Patent Litigation Tactics
Patent litigation and broader IP strategy are becoming increasingly intertwined with competition law considerations, as the boundaries between legitimate IP enforcement and anti-competitive conduct continue to evolve across global markets. This panel examines the evolving interaction between life science patent practices and competition law, focusing on how antitrust scrutiny is shaping enforcement decisions, licensing approaches, settlement frameworks and patent prosecution strategies across the IP landscape.
- Hear the latest innovator and generics perspectives on life science competition.
- Assess where the European Commission and international competition authorities are drawing the line between legitimate portfolio optimisation and anti-competitive IP gaming.
- Explore how new measures under the EU Pharma Package and Biotech Act, including supply obligations, launch incentives and transferable exclusivity vouchers, will interact with competition law in Europe.
- Review the May 2026 U.S. District Court for the District of Massachusetts verdict in the Amitiza “pay-for-delay” antitrust litigation and discuss its implications for how life science companies should structure future patent settlements.
- Examine how competition law intersects with patent linkage frameworks, regulatory practice and Hatch-Waxman-style ANDA litigation in the U.S. and China.
